An analysis of real-world patient outcomes in treatment for anaplastic large cell lymphoma (sALCL) has shown the importance of assessing care outside clinical trials, say researchers. The retrospective study of 214 patients treated at seven centres in Australia and the UK found inferior time to treatment failure with standard CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) regimens ...
Real-world data sets benchmark in ALCL as new therapies are adopted
By Emma Wilkinson
4 Jun 2021